2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170839
    TRPV1-IN-3 87657-67-8 98%
    TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC50=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345).
    TRPV1-IN-3
  • HY-170846
    FGFRs-IN-1 98%
    FGFRs-IN-1 (Compound A16) is the orally active inhibitor for FGFR, that inhibits FGFR1/2/3/4 with IC50s of 2.3, 7, 11, and 163 nM, respectively. FGFRs-IN-1 also inhibits VEGFR1/2/3, Abl, and Flt3 with IC50s of 61, 176, 112, 26, and 353 nM, respectively. FGFRs-IN-1 exhibits weak inhibitory efficacy against CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and inhibits epithelial-mesenchymal transition (EMT) in TGF-β1 stimulated A549 cell. FGFRs-IN-1 exhibits anti-inflammatory activity in Bleomycin (HY-17565)-induced mouse pulmonary fibrosis model and CCl4 (HY-Y0298)-induced mouse liver fibrosis model.
    FGFRs-IN-1
  • HY-170851
    GL392 98%
    GL392 is a senolytic agent that selectively delivers the potent senolytic compound Dasatinib (HY-10181) to senescent cells. GL392 targets lipofuscin in senescent cells via the LBD domain and is linked to Dasatinib through an ester bond. Upon internalization in senescent cells, Dasatinib is released, inducing apoptosis of the senescent cells. GL392 in micelle encapsulation (mGL392) enables selective delivery to senescent cells, achieving selective senescent cell elimination in vitro and in vivo. GL392 can be used for the research of melanoma.
    GL392
  • HY-170887
    MAO-B-IN-39 3094045-97-0 98%
    MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress)-related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research.
    MAO-B-IN-39
  • HY-170896
    iso-A11B5C1 3063868-70-9
    Iso-A11B5C1 is an ionizable lipid that can be used in the synthesis of lipid nanoparticles (LNP). Iso-A11B5C1 is particularly suitable for muscle-specific mRNA delivery.
    iso-A11B5C1
  • HY-170904
    NLRP3-IN-72 3043952-13-9 98%
    NLRP3-IN-72 (Compound 2) is a benzimidazole derivative. NLRP3-IN-72 exhibits anti-inflammatory and antioxidant activities. NLRP3-IN-72 has an IC50 of 0.3 μM for NLRP3 IL-1β, a PD50 of 0.4 μM for protecting against pyroptosis, and an EC50 of 0.6 μM for inducing HO-1.
    NLRP3-IN-72
  • HY-170916
    Angiogenesis inhibitor 7 922029-50-3 98%
    Angiogenesis inhibitor 7 (compound BT2) ia a potent inhibitor of angiogenesis. Angiogenesis inhibitor 7 inhibits ERK phosphorylation, FosB/ΔFosB and VCAM-1 expression.
    Angiogenesis inhibitor 7
  • HY-170950
    P2Y14 antagonist 1 98%
    P2Y14 antagonist 1 (compound 45) is a high selective and orally active P2Y14R antagonist with an IC50 of 0.70 nM. P2Y14R antagonist 1 demonstrates significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. P2Y14R antagonist 1 has the potential for the research of acute lung injury.
    P2Y14 antagonist 1
  • HY-170956
    BTN3A1 ligand-1 98%
    BTN3A1 ligand-1 (Compound 26b) is a triazole-containing aryl/acyloxyalkyl phosphonate prodrug. BTN3A1 ligand-1 can stimulate T cell proliferation (EC50 : 0.49 nM) and interferon γ secretion. BTN3A1 ligand-1 has certain plasma stability and can be used in related immunotherapy research.
    BTN3A1 ligand-1
  • HY-170957
    5-LOX/NO-IN-1 98%
    5-LOX/NO-IN-1 (Compound 7e) is a 5-LOX and NO release inhibitor. 5-LOX/NO-IN-1 shows an IC50 of 2.833 μM for 5-LOX. 5-LOX/NO-IN-1 has anti-inflammatory effects.
    5-LOX/NO-IN-1
  • HY-170977
    JAK1/STAT3-IN-1 98%
    JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting JAK1/STAT3 signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC50 of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on Calcipotriol (HY-10001) (MC903)-induced AD-like mice.
    JAK1/STAT3-IN-1
  • HY-170994
    I2-IRs ligand-1 98%
    I2-IRs ligand-1 (Compound 12d) is an orally active and BBB-penetrable compound. I2-IRs ligand-1 has a high affinity for imidazoline I2 receptors (I2-IRs) (pKi: 9.98). I2-IRs ligand-1 can improve cognitive impairment in senescent mice and exhibits analgesic, anti-inflammatory, and neuroprotective activities. I2-IRs ligand-1 can be used for the research of Alzheimer's disease and related pain disorders.
    I2-IRs ligand-1
  • HY-170998
    ATG16L1 stabilizer-1 98%
    ATG16L1 stabilizer-1 (compound A3B) is an FKBP12-independent ATG16L1 stabilizer that promotes cellular Autophagy. ATG16L1 stabilizer-1 inhibits ATG16L1 with an EC50 of 12.1 μM in the presence or absence of FKBP12. ATG16L1 stabilizer-1 alone induces GFP-LC3 puncta formation to a small extent with an EC50 of 12.0 μM.
    ATG16L1 stabilizer-1
  • HY-171001
    ZM522 1454575-38-2 98.50%
    ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. ZM522 effectively increases the levels of interferon-γ (INF-γ) and enhances immune activity by regulating the activation status of T cells. ZM522 holds promise for research in the fields of immunology and cancer therapy.
    ZM522
  • HY-171096
    PAR2 modulator-1 2378159-28-3 98%
    PAR2 modulator-1 (Compound C781) is a protease activated receptor type 2 (PAR2) antagonist. PAR2 modulator-1 can specifically inhibit the PAR2-dependent MAPK signaling pathway with an IC50 value of 8.5 μM. PAR2 modulator-1 can block the pain response triggered by PAR2 agonists. PAR2 modulator-1 can be used for the researches of inflammation, immunology and neurological disease, such as chronic pain and asthma.
    PAR2 modulator-1
  • HY-171172
    GSC-718 2493080-16-1 98%
    GSC-718 is a synthetic sialoside and is a ligand mimic for CD22. GSC-718 is a potent CD22 inhibitor with an IC50 of 0.161μM for mCD22. GSC-718 promote the proliferation of B cells and enhance antibody production. GSC-718 can be used for researches of B-cell lymphoma and rheumatoid arthritis.
    GSC-718
  • HY-171237
    mPGES1-IN-9 556033-92-2 98%
    mPGES1-IN-9 (compound 1_8) is a mPGES1 inhibitor (IC50=0.5 μM), which can be used in anti-inflammatory research.
    mPGES1-IN-9
  • HY-171279
    Casein kinase 1δ-IN-29 1177418-39-1 98%
    Casein kinase 1δ-IN-29 (Compound 18) is the inhibitor for p38α and casein kinase 1 that inhibits p38α, CK1δ and CK1ε with IC50 of 0.041 µM, 0.005 µM and 0.447 µM, respectively. Casein kinase 1δ-IN-29 arrests cell cycle at subG1 phase, induces apoptosis in cell AC1-M88.
    Casein kinase 1δ-IN-29
  • HY-171290
    Casein kinase 1δ-IN-31 2567490-30-4 98%
    Casein kinase 1δ-IN-31 (Compound 16) is the inhibitor for casein kinase (CK) that inhibits CK1α, CK1δ, and p38α with IC50s of 196, 17, and 18 nM, respectively. Casein kinase 1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with IC50 of 1200 nM.
    Casein kinase 1δ-IN-31
  • HY-171297
    p38-α MAPK-IN-10 200801-77-0 98%
    p38-α MAPK-IN-10 (Compound 6) is the inhibitor for p38α with an IC50 of 4 nM.
    p38-α MAPK-IN-10
Cat. No. Product Name / Synonyms Application Reactivity